Cellectar Awarded $2.0M Phase II NIH SBIR Grant To Support Pivotal Study Of Iopofosine I-131 In Waldenstrom’s Macroglobulinemia
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a